This is a Phase 3, global, double-blind, randomized, placebo-controlled study of adjunctive GNX treatment in children and adults with TSC-related epilepsy. The study consists of a 4-week prospective Baseline phase, defined as the first 28 days…
- Investigator
- Yue Wang
- Status
- Accepting Candidates
- Ages
- 1 Year - 65 Years
- Sexes
- All